EX-10.3



 Exhibit 10.3 

AMENDED AND RESTATED EMPLOYMENT AGREEMENT 

This Amended and Restated Employment Agreement (the “Agreement”) is entered into as of May 12, 2015 by and between OXiGENE,
Inc., a Delaware corporation (the “Company”), and Dr. David Chaplin, an individual (the “Executive”). 
 W I T N
E S S E T H: 
 WHEREAS, the Company previously retained Executive to serve as the Company’s Chief Executive Officer pursuant to
the terms of an Employment Agreement dated May 16, 2014, which was amended by Amendment No. 1 to Employment Agreement dated August 7, 2014 (as amended, the “Prior Agreement”); 

WHEREAS, the Company desires to retain Executive to serve as the Company’s Chief Scientific Officer and Executive has agreed to serve as
the Company’s Chief Scientific Officer; and 
 WHEREAS, the Company and Executive desire to enter into this Agreement to set forth the
terms and conditions on which Executive will serve as the Company’s Chief Scientific Officer, which shall supersede and replace in its entirety the Prior Agreement; 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby mutually acknowledged, the Company and
Executive hereby agree as follows: 
  

	1.	Employment.  

 1.1 Executive shall serve in the capacity of Chief Scientific Officer, and shall have the
duties, responsibilities and authority assigned to Executive by the Company’s Chief Executive Officer and Board of Directors, to whom he shall report. Executive shall remain on the Board and shall serve in that capacity until such time as the
termination of his employment with the Company. Executive agrees that, upon the effective date of his termination, he shall resign any and all Board positions, with such resignation to take effect on the effective date of his termination. 

1.2 In addition, the Executive will agree to serve at the Company’s request from time to time as a research scholar or guest lecturer at the academic
institutions with which the Company maintains a business relationship, including without limitation, Baylor University, UT Southwestern, the University of Florida and/or Albert Einstein College of Medicine, Yeshiva University. 

1.3 Executive, so long as he is employed hereunder, (i) shall devote substantially all of his full professional time and attention to the services
required of him as an employee of the Company, except as otherwise agreed and except as permitted in accordance with paid vacation time subject to the Company’s existing vacation policy, and subject to the Company’s existing policies
pertaining to reasonable periods of absence due to sickness, personal injury or other disability, (ii) shall use his best efforts to promote the interests of the Company, and (iii) shall discharge his responsibilities in a diligent and
faithful manner, consistent with sound business practices. 







 1.4 Notwithstanding the above, Executive may continue to serve as a consultant/advisor for the entities listed on
Exhibit A provided that such service does not create any conflicts, ethical or otherwise, with Executive’s responsibilities to the Company and further provided that Executive’s time commitments do not unreasonably interfere with his
fulfillment of his responsibilities hereunder, as determined by the Company. 
 1.5 Executive shall perform his duties and responsibilities, and exercise
his authority pursuant to this Agreement exclusively within the United States of America. Without limiting the foregoing sentence, Executive is specifically prohibited from performing any of his duties or exercising his authority as Chief Scientific
Officer within the United Kingdom. Executive’s violation of the restrictions set forth in this Section 1.5 shall constitute a material breach of this Agreement. 
  

	2.	Term. 

 The term of Executive’s employment under this Agreement shall commence on the date hereof
and shall continue until terminated by either party in accordance with Section 6 hereof (the “Employment Term”). 
  

	3.	Base Salary; Annual Bonus; Stock Options. 

 3.1 During the Employment Term, Executive initially
shall be paid an annual base salary in the amount of $130,000 (such amount as adjusted, from time to time, the “Base Salary”), payable in biweekly (26) installments in accordance with the Company’s payroll schedule from time to
time in effect. The Base Salary will be subject to review annually or on such periodic basis (not to exceed annually) as the Company reviews the compensation of its other senior executives and may be adjusted upwards in the sole discretion of the
Company’s Board of Directors (the “Board”) or its designee. 
 3.2 Executive will be eligible during each year of the Employment Term for
consideration for an annual bonus (the “Annual Bonus”) equal to up to thirty-five percent (35%) of his then-current Base Salary, based upon the Company’s assessment of the performance of Executive and the Company, at its sole
discretion, to be paid prior to March 15th of the year following the year in which the Annual Bonus is earned. The Annual Bonus is based on the achievement of individual and Company written goals established on an annual basis and on overall
Company performance. Executive shall be eligible for a pro-rated Annual Bonus for 2015. The Board may in its discretion award Executive a more generous bonus. 

3.3 Executive will be eligible to receive equity-based awards pursuant to and in accordance with the terms of the Company’s 2015 Stock Plan and to
participate in any equity compensation plan that may be established by the Company for Executive or its executive team generally. 

  
 2 









	4.	Benefits. 

 Executive shall be entitled to participate in employee benefit plans and arrangements made
available by the Company generally to its employees of comparable title or responsibilities during the Employment Term. In addition, the Company shall (i) reimburse Executive or pay on his behalf the costs of living expenses when travelling on
Company business, and (ii) reimburse Executive or pay on his behalf the cost of one, business class roundtrip ticket between San Francisco and London per month. 
  

	5.	Business Expenses. 

 Executive shall be entitled to receive an American Express Corporate Card (or other
card should the Company change to another card issuer), for business related expenses and prompt reimbursement will be made for all reasonable and customary expenses incurred by him in performing services hereunder during the Employment Term,
provided that such expenses are incurred and accounted for in accordance with the policies and procedures established by the Company. 
  

	6.	Termination. 

 6.1 Executive’s employment will terminate effective on the date of his death. 

6.2 The Company may terminate Executive’s employment upon thirty (30) days’ prior written notice if Executive becomes Disabled. Executive will
be considered Disabled if he is unable to perform the essential functions of his position as Chief Scientific Officer, with or without a reasonable accommodation, for a period of ninety (90) calendar days, whether or not consecutive, within any
rolling twelve (12) month period. 
 6.3 The Company may terminate Executive’s employment on contemporaneous written notice for Cause. Cause
means: (a) Executive’s substantial failure to perform any of his duties as Chief Scientific Officer or to follow reasonable, lawful directions of the Chief Executive Officer or the Board; (b) Executive’s willful misconduct or
willful malfeasance in connection with his employment; (c) Executive’s commission of, conviction of, or plea of nolo contendere to, any crime constituting a felony under the laws of the United States or any state thereof, or any
other crime involving moral turpitude; (d) Executive’s material breach of any provision of this Agreement, the Company’s bylaws or any other written agreement with the Company; (e) Executive’s engaging in misconduct that
causes significant injury to the Company, financial or otherwise, or to its reputation; or (f) any act, omission or circumstance constituting cause under the law governing this Agreement. 

6.4 The Company may terminate Executive’s employment without Cause on sixty (60) days’prior written notice to the Executive. 

6.5 Executive may resign his employment without Good Reason on thirty (30) days’ prior written notice to the Company. 

6.6 Executive may resign his employment for Good Reason, provided that within ninety (90) days following the occurrence of the event of Good Reason,
Executive gives the Company 

  
 3 








 
written notice of the event pursuant to Section 15, the Company has thirty (30) days after the date the Company receives the notice to cure the event, and if the Company fails to cure
the event, Executive resigns his employment within sixty (60) days of the notice date. Good Reason means the Company: (a) materially reduces Executive’s title, or responsibilities; (b) relocates its U.S. headquarters more than
sixty (60) miles from their current location (unless the relocation results in the headquarters being closer to Executive’s residence); (c) materially reduces Executive’s Base Salary; or (d) breaches a material term of this
Agreement. Good Reason must also meet the requirements for a good reason termination in accordance with IRS Code Treasury Regulation §1.409A-1(n)(2), and any successor statute, regulation and guidance thereto. 

6.7. Executive agrees to resign any and all Board and officer positions upon the termination of his employment for any reason, which resignations shall take
effect on the effective date of the termination of his employment. 
  

	7.	Payments on Termination. 

 7.1 If the Company terminates Executive’s employment for Cause under
Section 6.3, because of Executive’s death under Section 6.1 or because Executive becomes Disabled under Section 6.2, or Executive resigns his employment without Good Reason under Section 6.5, the Company shall provide to
Executive the following termination compensation: 
 (a) a payment equal to the portion of Executive’s Base Salary that has accrued
prior to the termination that has not yet been paid; 
 (b) to the extent required by law and the Company’s written vacation policy, an
amount equal to the value of the Executive’s accrued but unused vacation days, calculated at a rate of $846.15 per day; 
 (c) the
amount of any expenses properly incurred by Executive on behalf of the Company prior to the termination and not yet reimbursed; and 
 (d)
the Annual Bonus related to the most recently completed calendar year, if earned and not already paid ((a) through (d) collectively, the “Accrued Obligations”). 

The payments described in Sections 7.1(a), (b) and (d), shall be payable on Executive’s last day of employment, or as otherwise allowable by law.
The expense reimbursement described in Section 7.1(c) shall be payable on Executive’s last day of employment, or on the earliest practicable date after Executive provides proof of the expenses and their business purpose. 

7.2 If the Company terminates Executive’s employment without Cause under Section 6.4 or Executive resigns his employment with Good Reason under
Section 6.6, the Company will provide Executive the following termination compensation: 
 (a) the Accrued Obligations, payable in
accordance with terms of Section 7.1 above; 
 (b) payments equal to Executive’s then-current Base Salary for a period of twelve
(12) months, payable on the Company’s normal paydays; and 

  
 4 








 (c) should Executive timely elect and be eligible for COBRA coverage, payment of Executive’s
COBRA premiums for Executive and Executive’s immediate family’s medical and dental insurance coverage for a period of twelve (12) months; provided, that the Company shall have no obligation to provide such coverage if Executive
becomes eligible for medical and dental coverage with another employer, provided that if the payment of the Executive’s premiums would violate the nondiscrimination rules or cause the reimbursement of claims to be taxable under the Patient
Protection and Affordable Care Act of 2010 or Section 105(h) of the Code, the Company paid premiums shall be treated as taxable payments and be subject to imputed income tax treatment to the extent necessary to eliminate any discriminatory
treatment or taxation under the Patient Protection and Affordable Act or Section 105(h) of the Code. Executive shall give prompt written notice to the Company on attaining such eligibility. 

7.3 If the Company terminates Executive’s employment without Cause under Section 6.4 or Executive resigns his employment with Good Reason under
Section 6.6 in the one year period following the effective date of a Change in Control, the Company will provide Executive the following termination compensation: 

(a) the Accrued Obligations, payable in accordance with terms of Section 7.1 above; 

(b) A lump sum payment of an amount equal to twelve (12) months of Executive’s then current Base Salary; 

(c) all stock options, stock appreciation rights, restricted stock, and other incentive compensation granted to Executive by the Company shall
vest and be immediately exercisable and Executive may exercise all such vested options and rights, and shall receive payments and distributions accordingly; and 

(d) should Executive timely elect and be eligible for COBRA coverage, payment of Executive’s COBRA premiums for Executive and
Executive’s immediate family’s medical and dental insurance coverage for a period of twelve (12) months; provided, that the Company shall have no obligation to provide such coverage if Executive becomes eligible for medical and dental
coverage with another employer, provided that if the payment of the Executive’s premiums would violate the nondiscrimination rules or cause the reimbursement of claims to be taxable under the Patient Protection and Affordable Care Act of 2010
or Section 105(h) of the Code, the Company paid premiums shall be treated as taxable payments and be subject to imputed income tax treatment to the extent necessary to eliminate any discriminatory treatment or taxation under the Patient
Protection and Affordable Act or Section 105(h) of the Code. Executive shall give prompt written notice to the Company on attaining such eligibility. 

Change in Control means: (i) any “Person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended)
becomes the “Beneficial Owner” (as defined in Rule 13d-3 under said Act), directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the total voting power represented by the Company’s then
outstanding voting securities (excluding for this purpose any such voting securities held by the Company or its affiliates or by any employee benefit plan of the Company) pursuant to a transaction or a series of related transaction which the Board
of Directors does not approve; (ii) a merger or consolidation of the Company whether or not approved by the Board of Directors, 

  
 5 








 
other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or
by being converted into voting securities of the surviving entity or the parent of such corporation) at least 50% of the total voting power represented by the voting securities of the Company or such surviving entity or parent of such corporation,
as the case may be, outstanding immediately after such merger or consolidation; (iii) the stockholders of the Company approve an agreement for the sale or disposition by the Company of all or substantially all of its assets; or (iv) a
change in the composition of the Board of Directors, as a result of which fewer than a majority of the directors are Incumbent Directors, and provided in each such case the Change in Control also meets the requirements of a “Change in Control
Event” within the meaning of Section 409A(a)(2)(A)(v) of the Code and Treasury Regulation Section 1.409A-3(i)(5). “Incumbent Directors” mean the directors who either (A) are directors of the Company as of the date of
this Agreement, or (B) are elected, or nominated for election, to the Board of Directors with the affirmative votes of at least a majority of the Incumbent Directors at the time of such election or nomination (but shall not include an
individual whose election or nomination is in connection with an actual or threatened proxy contest relating to the election of directors to the Company). 

7.4 The payments described in Sections 7.2(b), (c) and (d), and Sections 7.3(b), (c), (d) and (e), shall be paid or commence to be paid within ninety
(90) days of Executive’s termination of employment, provided that prior to the expiration of the ninety (90) day period, Executive has delivered to the Company a general release of claims in a form determined by the Company and the
release has become enforceable and irrevocable. If the ninety (90) day period begins in one tax year and ends in the following tax year, the payments will commence in the following tax year. In all cases, the first payment will include all
amounts that would have been paid to Executive under Sections 7.2(b), (c) and (d), and Sections 7.3(b), (c), (d) and (e), between the date the termination of Executive’s employment became effective and the first payment date. 

7.5 The foregoing payments upon Executive’s termination shall constitute the exclusive payments due Executive upon termination of his employment with the
Company under this Agreement or otherwise, provided, however that except as stated above, such payments shall have no effect on any benefits which may be payable to Executive under any plan of the Company which provides benefits after termination of
employment. 
  

	8.	Taxes.  

 Any amounts or benefits payable or provided to Executive under this Agreement
shall be paid or provided to Executive subject to all applicable taxes required to be withheld by the Company pursuant to relevant federal, state and/or local law. Executive shall be solely responsible for all taxes imposed on Executive by reason of
his receipt of any amounts of compensation or benefits payable hereunder. The Company makes no representation, warranty or promise regarding the tax treatment of any payment or benefit provided to Executive. 

 

	8	Confidentiality; Non-Solicitation.  


  
 6 








 8.1 The Confidentiality and Inventions Agreement previously signed by Executive shall continue in full force and
effect in accordance with its terms. 
 8.2 While Executive is employed by the Company, and for a period of twelve (12) months following the
termination of his employment, neither Executive nor any Executive-Controlled Person (as defined below) will, without the prior written consent of the Company, directly or indirectly solicit for employment, or make an unsolicited recommendation to
any other person that it employs or solicits for employment any person who is or was, at any time during the one (1) year period prior to the termination date, an officer, Executive or key employee of the Company or any affiliate of the
Company. As used in this Agreement, the term “Executive-Controlled Person” means any company, partnership, firm or other entity as to which Executive possesses, directly or indirectly, the power to
direct or cause the direction of the management and policies of such entity, whether through the ownership of voting securities, by contract or otherwise. 

8.3 Executive agrees that the provisions of this Section 8 are reasonable and necessary for the Company’s protection and that they may not be
adequately enforced by an action for damages and that, in the event of a material breach of this Section 8 by Executive or any Executive-Controlled Person, the Company shall be entitled to apply for and obtain injunctive relief in any court of
competent jurisdiction to restrain the breach or threatened breach of such violation or otherwise to enforce specifically such provisions against such violation, without the necessity of the posting of any bond by the Company. Executive further
covenants under this Section 8 that the Company shall be entitled to an accounting and repayment of all profits, compensation, commissions, remuneration or other benefits that Executive directly or indirectly has realized and/or may realize as
a result of, growing out of or in connection with any such violation. Such remedy shall, however, be cumulative and not exclusive and shall be in addition to any injunctive relief or other legal equitable remedy to which the Company is or may be
entitled. 
  

	9	Indemnification  

 The Company, to the extent permitted by its Articles and By Laws, shall indemnify
Executive for all claims, losses, expenses, costs, obligations, and liabilities of every nature whatsoever incurred by Executive to any third party as a result of Executive’s acts or omissions as an employee of the Company, but excluding from
such indemnification any claims, losses, expenses, costs, obligations, or liabilities incurred by Executive as a result of Executive’s bad faith, willful misconduct or gross negligence. 

 

	10	Attorney’s Fees and Expenses 

 The Company and Executive agree that in the event of litigation
arising out of or relating to this Agreement, the prevailing party shall be entitled to reimbursement from the other party to the prevailing party’s reasonable attorney fees and expenses. Reimbursements under this Section 10 will be paid
within sixty (60) days from the date it is determined that Executive is entitled to payment under this Section 10. 

  
 7 









	11	Amendments  

 This Agreement may not be altered, modified or amended except by a written instrument
signed by each of the parties hereto. 
  

	12	Assignments  

 Neither this Agreement nor any of the rights or obligations hereunder shall be assigned or
delegated by any party hereto without the prior written consent of the other party; provided, however, that any payments and benefits owed to Executive under this Agreement shall inure to the benefit of his heirs and personal
representatives. 
  

	13	Waiver.  

 Waiver by any party hereto of any breach or default by any other party of any of the terms of
this Agreement shall not operate as a waiver of any other breach or default, whether similar to or different from the breach or default waived. 
  

	14	Severability  

 In the event that any one or more of the provisions of this Agreement shall be or become
invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not be affected thereby. 
  

	15	Notices  

 All notices and other communications provided for in this Agreement shall be in writing and
shall be deemed to have been duly given when personally delivered or when mailed by registered mail, return receipt requested, postage prepaid, addressed as follows: 

If to Executive: 
 Dr. David Chaplin 

If to OXiGENE: 
 OXiGENE, Inc. 

701 Gateway Boulevard, Suite 210 
 South San Francisco, CA 94080

 Attn: Chair of the Board of Directors 
 Or to such other
address or such other person as Executive or the Company shall designate in writing in accordance with this Section 15, except that notices regarding changes in notices shall be effective only upon receipt. 

  
 8 









	16	Headings  

 Headings to Sections in this Agreement are for the convenience of the parties only and are
not intended to be a part of, or to affect the meaning or interpretation of, this Agreement. 
  

	17	Governing Law; Venue 

 This Agreement shall be governed by the laws of the state of California without
reference to the principles of conflict of laws. Each of the parties hereto consents to the exclusive jurisdiction of the federal and state courts of the state of California in connection with any claim or controversy arising out of or connected
with this Agreement, and said courts shall be the exclusive fora for the resolution of any such claim or controversy. Service of process in any such proceeding may be made upon each of the parties hereto at the address of such party as determined in
accordance with Section 15 of this Agreement, subject to the applicable rules of the court in which such action is brought. 
  

	18	All Other Agreements Superseded 

 This Agreement and the Executive’s Confidentiality and Inventions
Agreement collectively contain the entire agreement between Executive and the Company with respect to all matters relating to Executive’s employment with the Company and, as of the date hereof, supersede and replace any other agreements,
written or oral, between the parties relating to the terms or conditions of Executive’s employment with the Company including, without limitation, the Prior Agreement. 
  

	19	Compliance with Code Section 409A 

 19.1 If any of the benefits set forth in this Agreement are deferred
compensation under Section 409A of the Internal Revenue Code of 1986, as amended, or any successor statute, regulation and guidance thereto (“Code Section 409A”), any termination of employment triggering payment of such benefits
must constitute a “separation from service” under Code Section 409A before distribution of such benefits can commence. For purposes of clarification, this paragraph shall not cause any forfeiture of benefits on the part of Executive,
but shall only act as a delay until such time as a “separation from service” occurs. 
 19.2 It is intended that each installment of the payments
and benefits provided under this Agreement shall be treated as a separate “payment” for purposes of Code Section 409A. Neither the Company nor Executive shall have the right to accelerate or defer the delivery of any such payments or
benefits except to the extent specifically permitted or required by Code Section 409A. 
 19.3 Any reimbursements or direct payment of Executive’s
expenses subject to Code Section 409A shall be made no later than the end of the calendar year following the calendar year in which such expense is incurred by Executive. Any reimbursement or right to direct payment of Executive’s expense
in one calendar year shall not affect the amount that may be reimbursed or paid for in any other calendar year and a reimbursement or payment of Executive’s expense (or right thereto) may not be exchanged or liquidated for another benefit or
payment. 

  
 9 








 19.4 Notwithstanding any other provision of this Agreement to the contrary, the Agreement shall be interpreted
and at all times administered in a manner that avoids the inclusion of compensation in income under Code Section 409A(a)(1), such that if a provision is ambiguous and may be interpreted in a manner that complies with Code
Section 409A(a)(1), the parties intend that interpretation to apply. For purposes of clarification, this Section 19.4 shall be a rule of construction and interpretation and nothing in this Section 19.4 shall cause a forfeiture of
benefits on the part of Executive. 
 19.5 Notwithstanding any other provision of this Agreement to the contrary, if any amount (including imputed income)
to be paid to Executive pursuant to this Agreement as a result of Executive’s termination of employment is “deferred compensation” subject to Code Section 409A, and if Executive is a “Specified Employee” (as defined
under Code Section 409A) as of the date of Executive’s termination of employment hereunder, then, to the extent necessary to avoid the imposition of excise taxes or other penalties under Code Section 409A, the payment of benefits, if
any, scheduled to be paid by Company to Executive hereunder during the first six (6) month period following the date of a termination of employment hereunder shall not be paid until the date which is the first business day after six
(6) months have elapsed since Executive’s termination of employment for any reason other than death. Any deferred compensation payments delayed in accordance with the terms of this Section 19.5 shall be paid in a lump sum after six
(6) months have elapsed since Executive’s termination of employment. Any other payments will be made according to the timing provided for herein. 

[Signature page follows] 

  
 10 








 IN WITNESS WHEREOF, OXiGENE and Executive have caused this Agreement to be executed as of the
date first above written. 
  

							
	OXIGENE, INC.	 		 	DR. DAVID CHAPLIN
				
	By:	 	 /s/ Frederick W. Driscoll
	 		 	 /s/ Dr. David Chaplin

	Name:	 	Frederick W. Driscoll	 		 	
	Title:	 	Chairman of the Board	 		 	








 Exhibit A 

ACCEPTABLE ONGOING OUTSIDE SERVICES 
 Services for OXiGENE in
the United Kingdom pursuant to a consulting agreement between OXiGENE and Aston Biopharma, Ltd., United Kingdom 
 Services for International Discovery
Services and Consulting pursuant to consulting agreement with International Discovery Services and Consulting, Michigan 
 Services as director for Smart
Matrix, Ltd., United Kingdom 
 Services as director for PHusis Therapeutics, Inc., California 

  
 12